Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$566M |
| 2 |
Meta Platforms (Facebook)
META
|
+$401M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$366M |
| 4 |
Align Technology
ALGN
|
+$356M |
| 5 |
PayPal
PYPL
|
+$278M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$564M |
| 2 |
Alibaba
BABA
|
+$511M |
| 3 |
Altria Group
MO
|
+$439M |
| 4 |
Revvity
RVTY
|
+$321M |
| 5 |
Merck
MRK
|
+$316M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.77% |
| 2 | Healthcare | 19.73% |
| 3 | Consumer Discretionary | 11.5% |
| 4 | Financials | 9.61% |
| 5 | Communication Services | 8.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMA
1101
DELISTED
Comerica
CMA
| $1.46M | ﹤0.01% |
38,191
+5,160
| +16% | +$198K |
|
1102
Copa Holdings
CPA
$5.56B
| $1.44M | ﹤0.01% |
28,514
-770
| -3% | -$38.9K |
|
1103
Vanguard FTSE All-World ex-US ETF
VEU
$64.8B
| $1.43M | ﹤0.01% |
28,352
-12,072
| -30% | -$612K |
|
|
SYNH
1104
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $1.42M | ﹤0.01% |
26,618
-2,757
| -9% | -$164K |
|
1105
Arrow Electronics
ARW
$10.5B
| $1.4M | ﹤0.01% |
17,850
-102,061
| -85% | -$7.54M |
|
1106
Fulcrum Therapeutics
FULC
$241M
| $1.4M | ﹤0.01% |
+177,166
| New | +$2.13M |
|
1107
Supernus Pharmaceuticals
SUPN
$2.7B
| $1.4M | ﹤0.01% |
67,127
+5,512
| +9% | +$125K |
|
1108
State Street SPDR S&P Homebuilders ETF
XHB
$1.61B
| $1.39M | ﹤0.01% |
+25,722
| New | +$1.3M |
|
1109
American Well
AMWL
$180M
| $1.38M | ﹤0.01% |
+2,325
| New | +$1.23M |
|
1110
Innoviva
INVA
$1.6B
| $1.35M | ﹤0.01% |
129,238
+9,522
| +8% | +$121K |
|
1111
John Wiley & Sons Class A
WLY
$2.83B
| $1.33M | ﹤0.01% |
41,967
-89
| -0.2% | -$3.02K |
|
|
HDS
1112
DELISTED
HD Supply Holdings, Inc.
HDS
| $1.32M | ﹤0.01% |
32,016
+2,975
| +10% | +$114K |
|
1113
Steel Dynamics
STLD
$36.2B
| $1.31M | ﹤0.01% |
45,783
+3,078
| +7% | +$88.3K |
|
1114
Credicorp
BAP
$30.5B
| $1.3M | ﹤0.01% |
10,455
-5,955
| -36% | -$765K |
|
1115
Castle Biosciences
CSTL
$742M
| $1.29M | ﹤0.01% |
25,087
+4,477
| +22% | +$199K |
|
|
MODV
1116
DELISTED
ModivCare
MODV
| $1.28M | ﹤0.01% |
+13,800
| New | +$1.19M |
|
|
BKI
1117
DELISTED
Black Knight, Inc. Common Stock
BKI
| $1.28M | ﹤0.01% |
14,698
-58,479
| -80% | -$4.61M |
|
1118
Qualys
QLYS
$4.76B
| $1.27M | ﹤0.01% |
13,011
+749
| +6% | +$80.1K |
|
1119
ACM Research
ACMR
$4.51B
| $1.26M | ﹤0.01% |
54,585
-24,852
| -31% | -$706K |
|
1120
PUT
Tesla
TSLA
$1.18T
| $1.23M | ﹤0.01% |
+45,600
| New | +$5.38M |
|
1121
Owens Corning
OC
$11B
| $1.19M | ﹤0.01% |
17,351
-92,851
| -84% | -$5.95M |
|
1122
Cameco
CCJ
$36.8B
| $1.19M | ﹤0.01% |
117,603
-546,912
| -82% | -$5.92M |
|
1123
Southern Copper
SCCO
$138B
| $1.18M | ﹤0.01% |
28,185
+1,322
| +5% | +$54.9K |
|
|
LVGO
1124
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $1.18M | ﹤0.01% |
+8,398
| New | +$1.02M |
|
|
GBIO
1125
DELISTED
Generation Bio
GBIO
| $1.17M | ﹤0.01% |
3,781
-2,636
| -41% | -$630K |
|
Similar funds
Janus Henderson Group's Q3 2020 Portfolio in Review
As of Q3 2020, Janus Henderson Group held 1,403 positions worth $192B, up 7.7% from $178B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Janus Henderson Group's Q3 2020 filing shows 105 new, 521 increased, 678 reduced and 86 closed positions. Its largest new stake was Acceleron Pharma: 1,783,939 shares worth $201M. The largest sale was Apple, an estimated $564M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q3 2020 buy was Acceleron Pharma: 1,783,939 shares worth $201M.
- Janus Henderson Group added most to Booking.com in Q3 2020, an estimated $566M increase.
- Janus Henderson Group's biggest Q3 2020 reduction was Apple, cutting an estimated $564M.
- Janus Henderson Group fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $49.5M.
- Janus Henderson Group's ten largest holdings make up 24% of its $192B portfolio in Q3 2020.
- Janus Henderson Group opened 105 new positions and closed 86 in Q3 2020.
- Janus Henderson Group's portfolio value rose 7.7% quarter-over-quarter to $192B.
Based on Janus Henderson Group's 13F filing for Q3 2020, filed 16 Nov 2020.